Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | CDK14 | O94921 | 1/20 | 0.37 |
| ▸ | CCNY | Q8ND76 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | CDK7 | P50613 | 3/20 | 0.37 |
| ▸ | CDK9 | P50750 | 2/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 4/20 | 0.36 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | ITK | Q08881 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20892752 | 0.91 | JAK3 (0.41) | JAK3CDK14CCNYCDK7CDK9 | |
| SCHEMBL20892949 | 0.91 | JAK3 (0.41) | JAK3CDK14CCNYCDK7CDK9 | |
| SCHEMBL21345775 | 0.88 | GAA (0.37) | JAK3CDK14CCNYHDAC1HDAC2 | |
| SCHEMBL20892791 | 0.86 | JAK3 (0.36) | JAK3CDK7CDK9CDK4BTK | |
| SCHEMBL17928309 | 0.84 | JAK3 (0.48) | JAK3CDK14CCNYCDK7CDK9 | |
| SCHEMBL2618873 | 0.84 | JAK3 (0.48) | JAK3CDK14CCNYCDK7CDK9 | |
| SCHEMBL410261 | 0.84 | JAK3 (0.48) | JAK3CDK14CCNYCDK7CDK9 | |
| SCHEMBL26469442 | 0.83 | JAK3 (0.45) | JAK3CDK7CDK9CDK4BTK | |
| SCHEMBL25066408 | 0.83 | CCR2 (0.42) | CCR2JAK3GAA | |
| SCHEMBL18909694 | 0.83 | BTK (0.39) | JAK3CDK14CCNYHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542249-B2 | BTK inhibitor compounds | ELI LILLY AND COMPANY (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220213106-A1 | Inhibitors of Bruton's Tyrosine Kinase | PHARMACYCLICS LLC (US) | 2022-07-07 | — | — | US | disclosed |
| EP-3707133-B1 | BTK INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20200290997-A1 | BTK INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2020-09-17 | — | — | US | disclosed |
| US-20200289515-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-20200276199-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC | 2020-09-03 | — | — | US | disclosed |
| US-20200055859-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2020-02-20 | — | — | US | disclosed |
| US-20180193345-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC | 2018-07-12 | — | — | US | disclosed |
| US-20180193345-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC | 2018-07-12 | — | — | US | disclosed |
| US-20180169094-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | MERCK PATENT GMBH (DE) | 2018-06-21 | — | — | US | disclosed |
| US-20120178753-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120165328-A1 | INHIBITORS OF B LYMPHOCYTE KINASE | PHARMACYCLICS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165328-A1 | INHIBITORS OF B LYMPHOCYTE KINASE | PHARMACYCLICS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120101113-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101114-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120065201-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110224235-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224235-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20100254905-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100254905-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178753-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | CCR2 3601/4885JAK3 253/4885CDK14 356/4885 |
| US-20220213106-A1 | Inhibitors of Bruton's Tyrosine Kinase | ABL1, BTK, ABL2 | CCR2 3601/4885JAK3 253/4885CDK14 356/4885 |
| US-20180169094-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | IRAK2, IRAK3, IRAK1 | CCR2 173/4885JAK3 70/4885CDK14 533/4885 |
| US-20120165328-A1 | INHIBITORS OF B LYMPHOCYTE KINASE | BLK, DCK, LTK | CCR2 1458/4885JAK3 453/4885CDK14 300/4885 |
| US-20180193345-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | CCR2 3482/4885JAK3 45/4885CDK14 202/4885 |
| US-20200289515-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | CCR2 3482/4885JAK3 45/4885CDK14 202/4885 |
| US-20120101114-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | CCR2 3601/4885JAK3 253/4885CDK14 356/4885 |
| US-20100254905-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | CCR2 3601/4885JAK3 253/4885CDK14 356/4885 |
| US-20200290997-A1 | BTK INHIBITOR COMPOUNDS | BTK, SYK, LCK | CCR2 1296/4885JAK3 23/4885CDK14 805/4885 |
| US-20200055859-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | ABL1, BTK, ABL2 | CCR2 3561/4885JAK3 190/4885CDK14 274/4885 |
| US-20120101113-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | CCR2 3601/4885JAK3 253/4885CDK14 356/4885 |
| US-20200276199-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | CCR2 3482/4885JAK3 45/4885CDK14 202/4885 |
| US-20110224235-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | CCR2 3482/4885JAK3 45/4885CDK14 202/4885 |
| US-20120065201-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | CCR2 3601/4885JAK3 253/4885CDK14 356/4885 |
| US-11542249-B2 | BTK inhibitor compounds | BTK, SYK, LCK | CCR2 1578/4885JAK3 25/4885CDK14 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.